Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral agent for the treatment of moderate to severe psoriasis that demonstrates improved efficacy and lasting remission when compared with Amgen/Wyeth/Takeda's Enbrel would earn a higher patient share in the United States than in Europe, according to surveyed US and European dermatologists.
An oral agent for the treatment of moderate to severe psoriasis would earn a higher patient share in the United States than in Europe